Study Results Show Shorter Radiation for Breast Cancer is ‘Worthy of Further Study’


An expert from the Mayo Clinic notes that there’s also a great amount of interest in further optimizing the dose of radiation after mastectomy, especially in patients with breast cancer immediately following reconstruction.

Optimizing the dose and fractionation regimen are some of the next steps in further developing postmastectomy radiation therapy in breast cancer, according to an expert from Mayo Clinic.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Robert Mutter, MD, a member of Mayo Clinic Cancer Center in Rochester, Minnesota, about future research for postmastectomy radiotherapy in the treatment of patients with breast cancer.

According to Mutter, future research in the field includes the RT CHARM trial (NCT03414970), which is evaluating photon postmastectomy radiation among patients who have undergone an immediate breast reconstruction.


There is an ongoing photon postmastectomy radiation trial for patients who have an immediate [breast] reconstruction. This is called the RT CHARM trial, and it’s actually completed accrual, so we’re eagerly awaiting those results, which should be sometime in late 2023, or 2024.

Our results suggest that hypofractionated proton postmastectomy radiation therapy is also worthy of further study. Certainly, there’s also a great interest in further optimizing the dose and fractionation regimen for postmastectomy radiation therapy, in particular, for patients with immediate reconstruction. These are patients who still have relatively high rates of complications whether they’re treated with photons, or, as we’ve seen in our study, with proton therapy because we observed similar rates of complications as what has been reported in the literature with photons.


Mutter R, Giri S, Fruth B, et al. Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy. Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX. Abstract GS4-05.

Related Videos
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Sean Dineen, MD, highlights the removal of abdominal wall lesions and other surgical strategies that may help manage symptoms in patients with cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.